Processa Pharmaceuticals ... (PCSA)
NASDAQ: PCSA
· Real-Time Price · USD
0.33
0.03 (9.78%)
At close: Jun 09, 2025, 3:59 PM
Processa Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 175.4K | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | 3.42M | 139.00 | 2.81M | 140.00 | 2.17M | 2.71M | 4.11M | 216.51K | 6.06M | 219.86K | 3.23M | 218.88K | 3.11M | 3.46M | 2.19M |
Gross Profit | n/a | n/a | -3.42M | -139 | -2.81M | -140 | -2.17M | -2.71M | -4.11M | -216.51K | -6.06M | -219.86K | -3.23M | -43.48K | -3.11M | -3.46M | -2.19M |
Operating Income | n/a | -2.73M | -3.42M | -3.08M | -5.62M | -2.47M | -2.17M | -2.71M | -4.11M | 1.47M | -6.06M | -5.17M | -3.23M | -3.37M | -3.11M | -3.46M | -2.19M |
Interest Income | n/a | 6.02K | 40.15K | n/a | 83.22K | 64.52K | 85.66K | 102K | 83.46K | 55.53K | 36.71K | 7.38K | 1.58K | 3.46K | 1.77K | 1.81K | 4.94K |
Pretax Income | -2.83M | -2.73M | -3.38M | -3.01M | -2.73M | -2.4M | -2.08M | -2.61M | -4.02M | -13.01M | -6.02M | -5.16M | -3.23M | -3.37M | -3.11M | -3.29M | -2.19M |
Net Income | -2.83M | -2.73M | -3.38M | -3.01M | -2.73M | -2.4M | -2.08M | -2.61M | 166.92K | -34.42M | -5.98M | -5.16M | -3.23M | -3.18M | -2.99M | -3.16M | -2.1M |
Selling & General & Admin | 1.26M | 1.02M | 1.14M | 1.35M | 1.27M | 1.15M | 1.02M | 1.03M | 2.48M | 2.63M | 2.92M | 2.03M | 1.18M | 1.3M | 1.34M | 1.33M | 717.15K |
Research & Development | 1.59M | 1.71M | 2.29M | 1.73M | 1.54M | 1.32M | 1.15M | 1.69M | 1.63M | 3.17M | 3.14M | 3.14M | 2.04M | 2.07M | 1.72M | 1.61M | 1.48M |
Other Expenses | n/a | n/a | n/a | 71.7K | n/a | -185.36K | n/a | 101.9K | 83.46K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 2.85M | 2.73M | 3.42M | 3.08M | 2.81M | 2.47M | 2.17M | 2.71M | 4.11M | 5.8M | 6.06M | 5.17M | 3.23M | 3.37M | 3.06M | 2.94M | 2.19M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 4.19M | n/a | n/a | n/a | 8.34M | 36.71K | n/a | 1.58K | 3.46K | 1.77K | 1.81K | 362.00 |
Selling & Marketing Expenses | n/a | n/a | n/a | -139 | n/a | -140 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 2.73M | 3.42M | 3.08M | 5.62M | 2.47M | 2.17M | 2.71M | 4.11M | 5.8M | 6.06M | 5.17M | 3.23M | 3.37M | 3.06M | 2.94M | 2.19M |
Income Tax Expense | n/a | n/a | n/a | n/a | -139 | 2.04M | 2.17M | -20.18K | -4.19M | 21.4M | -36.71K | 7.38K | -1.58K | -181.75K | -122.44K | -137.17K | -89.25K |
Shares Outstanding (Basic) | 9.53M | 3.7M | 3.28M | 2.98M | 2.47M | 1.89M | 1.35M | 1.35M | 1.14M | 823.11K | 810.01K | 797.02K | 791.55K | 787.3K | 776.57K | 770.32K | 729.18K |
Shares Outstanding (Diluted) | 9.53M | 3.7M | 3.28M | 2.98M | 2.47M | 1.89M | 1.35M | 1.35M | 1.14M | 823.11K | 810.01K | 797.02K | 791.55K | 787.3K | 776.57K | 770.32K | 729.18K |
EPS (Basic) | -0.3 | -0.83 | -1.03 | -1.01 | -1.1 | -1.3 | -1.5 | -1.9 | 0.15 | -41.8 | -7.4 | -6.4 | -4 | -4 | -3.8 | -4 | -2.8 |
EPS (Diluted) | -0.3 | -0.83 | -1.03 | -1.01 | -1.1 | -1.3 | -1.5 | -1.9 | 0.15 | -41.8 | -7.4 | -6.4 | -4 | -4 | -3.8 | -4 | -2.8 |
EBITDA | n/a | -2.73M | -3.42M | -3.08M | -2.81M | -2.47M | -2.17M | -2.59M | -4M | -5.6M | -5.86M | -4.97M | -3.03M | -3.17M | -2.89M | -3.07M | -1.97M |
EBIT | n/a | -2.73M | -3.42M | -3.08M | -2.81M | -2.47M | -2.17M | -2.71M | -4.11M | -5.8M | -6.06M | -5.17M | -3.23M | -3.37M | -3.06M | -3.29M | -2.19M |
Depreciation & Amortization | n/a | 301.00 | 203.00 | 139.00 | 139.00 | 140.00 | 82.00 | 20.18K | 19.8K | 216.51K | 217.96K | 219.86K | 219.68K | 218.88K | 217K | 219.7K | 219.77K |